Research
Energy balance
Dapagliflozin, an SGLT2 inhibitor, improves hyperglycemia and facilitates weight loss in type 2 diabetic patients by inducing controlled glucosuria, resulting in a urinary loss of approximately 200–300 kcal/day.
If you have type 2 diabetes, this medication works by having your kidneys flush out excess sugar through your urine. This process burns about 200-300 calories a day without you having to diet or exercise more, leading to modest weight loss and better blood sugar control. It is taken once daily.
GoodSupportsHIGH confidence
Dapagliflozin improved hyperglycemia and facilitates weight loss in type 2 diabetic patients by inducing controlled glucosuria with urinary loss of ~200–300 kcal/day.
Why this rating
Randomized, double-blind, placebo-controlled trial with 389 patients, though limited to 12 weeks.
Source
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al. · Diabetes Care · 2008
DOI 10.2337/dc08-1863
rct · n=389Cited 696×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →